- Home
- PLSE vs AUPH Comparison
PLSE vs AUPH Comparison
Compare PLSE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | AUPH |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.6B |
| IPO Year | 2016 | 1999 |
Fundamental Metrics
Financial Performance| Metric | PLSE | AUPH |
|---|---|---|
| Price | $14.90 | $15.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $22.00 | $17.25 |
| AVG Volume (30 Days) | 198.5K | ★ 1.1M |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $86,000.00 | ★ $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | $1,002.94 | $16.45 |
| P/E Ratio | ★ N/A | $28.07 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $12.56 | $6.55 |
| 52 Week High | $25.00 | $16.54 |
Technical Indicators
Market Signals| Indicator | PLSE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 50.95 |
| Support Level | $13.17 | $14.82 |
| Resistance Level | $15.05 | $15.98 |
| Average True Range (ATR) | 0.78 | 0.41 |
| MACD | 0.09 | -0.13 |
| Stochastic Oscillator | 67.03 | 48.84 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.